Tue, May 20, 8:32 PM (32 days ago)
**Greenwich LifeSciences, Inc. (GLSI) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** No revenue generated in Q1 2025. - **Profit Margins:** Negative, with a net loss of $3,258,362 (2024: $2,473,195). - **Cash Flow:** Net cash used in operating activities was $1,834,454 (2024: $1,782,565). Financing activities provided $492,423 (2024: $299,116) from ATM offerings. - **Earnings Changes:** Net loss per share increased to $0.25 (2024: $0.19). **Quarterly Performance Discussion:** - **Operating Expenses:** Increased by 28% to $3,282,332, driven by higher research and development (R&D) and general and administrative (G&A) expenses due to options grants. - **Cash Position:** Decreased to $2,749,959 from $4,091,990 in Q4 2024. **Trends & Uncertainties:** - **Going Concern:** Significant doubt about the ability to continue as a going concern due to net losses and negative cash flows. - **Funding:** Dependent on raising additional capital through equity and/or debt securities. - **Clinical Trials:** Expanding Flamingo-01 trial globally, which may increase costs. **Future Operations Impact:** - **Expenses:** Expect significant expenses and increased operating losses due to clinical trials and commercialization efforts. - **Liquidity:** Principal source of liquidity is cash, with plans to raise additional capital. **Key Metrics (in 000s):** - **Cash:** $2,749,959 (Mar 2025), $4,091,990 (Dec 2024) - **Total Assets:** $2,750,835 (Mar 2025), $4,093,769 (Dec 2024) - **Total Liabilities:** $1,438,524 (Mar 2025), $1,559,733 (Dec 2024) - **Stockholders' Equity:** $1,312,311 (Mar 2025), $2,534,036 (Dec 2024) - **Net Loss:** $3,258,362 (Q1 2025), $2,473,195 (Q1 2024) **Ticker:** GLSI **Note:** Amounts are in thousands (000s). The company is a smaller reporting company and an emerging growth company under the JOBS Act.